Legend Biotech Corp Adjustments For Unrealised Foreign Exchange Losses Gains
Legend Biotech Corp (LEGN) reported Adjustments For Unrealised Foreign Exchange Losses Gains of $168.80 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Income Statement › Other Income
ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains · last filed 2026-03-10
- Legend Biotech Corp adjustments for unrealised foreign exchange losses gains for the quarter ending 2025-12-31 was $3.40M.
- Legend Biotech Corp adjustments for unrealised foreign exchange losses gains for the quarter ending 2025-09-30 was $210.00K, a 99.66% decline year-over-year.
- Legend Biotech Corp adjustments for unrealised foreign exchange losses gains for the quarter ending 2025-06-30 was $109.99M.
- Legend Biotech Corp adjustments for unrealised foreign exchange losses gains for the quarter ending 2025-03-31 was $55.19M.
| Period end | Adjustments For Unrealised Foreign Exchange Losses Gains 3 month | Adjustments For Unrealised Foreign Exchange Losses Gains 6 month | Adjustments For Unrealised Foreign Exchange Losses Gains 9 month | Adjustments For Unrealised Foreign Exchange Losses Gains 12 month | Adjustments For Unrealised Foreign Exchange Losses Gains 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.40M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $3.62M derived: sum of 2 quarters · filed 2026-03-10 | $113.61M derived: sum of 3 quarters · filed 2026-03-10 | $168.80M 20-F · filed 2026-03-10 | |
| 2025-09-30 | $210.00K derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | $110.20M derived: sum of 2 quarters · filed 2025-11-12 | $165.40M 6-K · filed 2025-11-12 | $54.98M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-06-30 | $109.99M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | $165.19M 6-K · filed 2025-08-11 | $54.77M derived: sum of 3 quarters · filed 2026-03-10 | $116.59M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-03-31 | $55.19M 6-K · filed 2025-05-13 | -$55.22M derived: sum of 2 quarters · filed 2026-03-10 | $6.60M derived: sum of 3 quarters · filed 2026-03-10 | -$5.05M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-12-31 | -$110.41M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | -$48.60M derived: sum of 2 quarters · filed 2026-03-10 | -$60.24M derived: sum of 3 quarters · filed 2026-03-10 | -$109.30M 20-F · filed 2026-03-10 | -$109.35M 20-F · filed 2025-03-11 |
| 2024-09-30 | $61.81M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | $50.17M derived: sum of 2 quarters · filed 2025-11-12 | $1.11M 6-K · filed 2025-11-12 | $39.45M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-06-30 | -$11.65M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | -$60.70M 6-K · filed 2025-08-11 | -$22.37M derived: sum of 3 quarters · filed 2026-03-10 | -$39.52M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-03-31 | -$49.06M 6-K · filed 2025-05-13 | -$10.72M derived: sum of 2 quarters · filed 2026-03-10 | -$27.88M derived: sum of 3 quarters · filed 2026-03-10 | -$31.52M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2023-12-31 | $38.34M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $21.18M derived: sum of 2 quarters · filed 2026-03-10 | $17.54M derived: sum of 3 quarters · filed 2026-03-10 | $28.20M 20-F · filed 2026-03-10 | $28.22M 20-F · filed 2024-03-19 |
| 2023-09-30 | -$17.16M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | -$20.80M derived: sum of 2 quarters · filed 2024-11-12 | -$10.14M 6-K · filed 2024-11-12 | -$10.30M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | -$3.64M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | $7.02M 6-K · filed 2024-08-09 | $6.86M derived: sum of 3 quarters · filed 2025-03-11 | $6.58M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | $10.66M 6-K · filed 2024-05-13 | $10.50M derived: sum of 2 quarters · filed 2025-03-11 | $10.22M derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2022-12-31 | -$163.00K derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | -$440.00K derived: sum of 2 quarters · filed 2025-03-11 | $9.16M 20-F · filed 2025-03-11 | ||
| 2022-09-30 | -$277.00K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $9.32M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | $9.60M 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | $4.87M 20-F · filed 2024-03-19 | ||||
| 2021-06-30 | $703.00K 6-K · filed 2021-08-23 | ||||
| 2020-12-31 | -$66.00K 20-F · filed 2023-03-30 | ||||
| 2020-06-30 | $27.00K 6-K · filed 2021-08-23 | ||||
| 2019-12-31 | -$584.00K 20-F/A · filed 2023-02-17 | -$250.00K 20-F · filed 2021-04-02 | |||
| 2018-12-31 | -$7.24M 20-F · filed 2021-04-02 |